Insider buying
~$46K30K sh @ $1.52
Traded May 15, 2025 · filed the same day
An Omniab director paid $46K out of pocket for Omniab shares. 2 other people at Omniab bought some too, in the same month. Shares held went up 26% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
OABI · NASDAQ · Services-Commercial Physical & Biological Research
Omniab (OABI) · oqro.io/stocks/OABI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$5.03−0.05 (−0.98%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
2 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Insider buying
Traded May 15, 2025 · filed the same day
An Omniab director paid $46K out of pocket for Omniab shares. 2 other people at Omniab bought some too, in the same month. Shares held went up 26% with this purchase.
Insider buying
Traded May 14, 2025 · filed the same day
An Omniab director paid $37K out of pocket for Omniab shares. 2 other people at Omniab bought some too, in the same month. Shares held went up 188% with this purchase.
Insider buying
Traded May 12, 2025 · filed 1 day later
An Omniab director paid $94K out of pocket for Omniab shares. 2 other people at Omniab bought some too, in the same month.
Matthew W Foehr (President and CEO) sold ~$39K of Omniab
Automatic saleKurt A Gustafson (Executive VP, Finance and CFO) sold ~$14K of Omniab
Automatic saleCharles S Berkman (Chief Legal Officer) sold ~$14K of Omniab
Automatic saleKurt A Gustafson (Executive VP, Finance and CFO) sold ~$28K of Omniab
Automatic saleTraded Mar 20 – Mar 21, 2025 · largest single transaction ~$296K
Mar 20, 2025~$296K · 126K sh @ $2.35
DetailsOfficial recordMatthew W Foehr (President and CEO) sold ~$72K of Omniab
Automatic saleMatthew W Foehr (President and CEO) sold ~$51K of Omniab
Automatic saleKurt A Gustafson (Executive VP, Finance and CFO) sold ~$27K of Omniab
Automatic saleCharles S Berkman (Chief Legal Officer) sold ~$30K of Omniab
Automatic saleCharles S Berkman (Chief Legal Officer) sold ~$27K of Omniab
Automatic saleMatthew W Foehr (President and CEO) sold ~$135K of Omniab
Automatic saleKurt A Gustafson (Executive VP, Finance and CFO) sold ~$50K of Omniab
Automatic saleCharles S Berkman (Chief Legal Officer) sold ~$83K of Omniab
Automatic saleKurt A Gustafson (Executive VP, Finance and CFO) sold ~$99K of Omniab
Automatic saleMatthew W Foehr (President and CEO) sold ~$56K of Omniab
Automatic saleCharles S Berkman (Chief Legal Officer) sold ~$33K of Omniab
Automatic saleMar 21, 2025~$9.1K · 4,000 sh @ $2.28
DetailsOfficial record0 open-market purchases and 0 open-market sales by insiders of OABI between Feb 2, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 30, 2026. The data provider lists the next release for Mar 2, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Oct 30, 2026 | None | None | None |
| Aug 6, 2026 | None | None | None |
| May 7, 2026 | None | None | None |
| Mar 4, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies